Cargando…

Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy

Idiopathic inflammatory myopathies (IIMs), which are a group of chronic and diverse inflammatory diseases, are primarily characterized by weakness in the proximal muscles that progressively leads to persistent disability. Current treatments of IIMs depend on nonspecific immunosuppressive agents (inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamiya, Mari, Kimura, Naoki, Umezawa, Natsuka, Hasegawa, Hisanori, Yasuda, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361824/
https://www.ncbi.nlm.nih.gov/pubmed/37483632
http://dx.doi.org/10.3389/fimmu.2023.1191815
_version_ 1785076293260279808
author Kamiya, Mari
Kimura, Naoki
Umezawa, Natsuka
Hasegawa, Hisanori
Yasuda, Shinsuke
author_facet Kamiya, Mari
Kimura, Naoki
Umezawa, Natsuka
Hasegawa, Hisanori
Yasuda, Shinsuke
author_sort Kamiya, Mari
collection PubMed
description Idiopathic inflammatory myopathies (IIMs), which are a group of chronic and diverse inflammatory diseases, are primarily characterized by weakness in the proximal muscles that progressively leads to persistent disability. Current treatments of IIMs depend on nonspecific immunosuppressive agents (including glucocorticoids and immunosuppressants). However, these therapies sometimes fail to regulate muscle inflammation, and some patients suffer from infectious diseases and other adverse effects related to the treatment. Furthermore, even after inflammation has subsided, muscle weakness persists in a significant proportion of the patients. Therefore, the elucidation of pathophysiology of IIMs and development of a better therapeutic strategy that not only alleviates muscle inflammation but also improves muscle weakness without increment of opportunistic infection is awaited. Muscle fiber death, which has been formerly postulated as “necrosis”, is a key histological feature of all subtypes of IIMs, however, its detailed mechanisms and contribution to the pathophysiology remained to be elucidated. Recent studies have revealed that muscle fibers of IIMs undergo necroptosis, a newly recognized form of regulated cell death, and promote muscle inflammation and dysfunction through releasing inflammatory mediators such as damage-associated molecular patterns (DAMPs). The research on murine model of polymyositis, a subtype of IIM, revealed that the inhibition of necroptosis or HMGB1, one of major DAMPs released from muscle fibers undergoing necroptosis, ameliorated muscle inflammation and recovered muscle weakness. Furthermore, not only the necroptosis-associated molecules but also PGAM5, a mitochondrial protein, and reactive oxygen species have been shown to be involved in muscle fiber necroptosis, indicating the multiple target candidates for the treatment of IIMs acting through necroptosis regulation. This article overviews the research on muscle injury mechanisms in IIMs focusing on the contribution of necroptosis in their pathophysiology and discusses the potential treatment strategy targeting muscle fiber necroptosis.
format Online
Article
Text
id pubmed-10361824
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103618242023-07-22 Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy Kamiya, Mari Kimura, Naoki Umezawa, Natsuka Hasegawa, Hisanori Yasuda, Shinsuke Front Immunol Immunology Idiopathic inflammatory myopathies (IIMs), which are a group of chronic and diverse inflammatory diseases, are primarily characterized by weakness in the proximal muscles that progressively leads to persistent disability. Current treatments of IIMs depend on nonspecific immunosuppressive agents (including glucocorticoids and immunosuppressants). However, these therapies sometimes fail to regulate muscle inflammation, and some patients suffer from infectious diseases and other adverse effects related to the treatment. Furthermore, even after inflammation has subsided, muscle weakness persists in a significant proportion of the patients. Therefore, the elucidation of pathophysiology of IIMs and development of a better therapeutic strategy that not only alleviates muscle inflammation but also improves muscle weakness without increment of opportunistic infection is awaited. Muscle fiber death, which has been formerly postulated as “necrosis”, is a key histological feature of all subtypes of IIMs, however, its detailed mechanisms and contribution to the pathophysiology remained to be elucidated. Recent studies have revealed that muscle fibers of IIMs undergo necroptosis, a newly recognized form of regulated cell death, and promote muscle inflammation and dysfunction through releasing inflammatory mediators such as damage-associated molecular patterns (DAMPs). The research on murine model of polymyositis, a subtype of IIM, revealed that the inhibition of necroptosis or HMGB1, one of major DAMPs released from muscle fibers undergoing necroptosis, ameliorated muscle inflammation and recovered muscle weakness. Furthermore, not only the necroptosis-associated molecules but also PGAM5, a mitochondrial protein, and reactive oxygen species have been shown to be involved in muscle fiber necroptosis, indicating the multiple target candidates for the treatment of IIMs acting through necroptosis regulation. This article overviews the research on muscle injury mechanisms in IIMs focusing on the contribution of necroptosis in their pathophysiology and discusses the potential treatment strategy targeting muscle fiber necroptosis. Frontiers Media S.A. 2023-07-07 /pmc/articles/PMC10361824/ /pubmed/37483632 http://dx.doi.org/10.3389/fimmu.2023.1191815 Text en Copyright © 2023 Kamiya, Kimura, Umezawa, Hasegawa and Yasuda https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kamiya, Mari
Kimura, Naoki
Umezawa, Natsuka
Hasegawa, Hisanori
Yasuda, Shinsuke
Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title_full Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title_fullStr Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title_full_unstemmed Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title_short Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
title_sort muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361824/
https://www.ncbi.nlm.nih.gov/pubmed/37483632
http://dx.doi.org/10.3389/fimmu.2023.1191815
work_keys_str_mv AT kamiyamari musclefibernecroptosisinpathophysiologyofidiopathicinflammatorymyopathiesanditspotentialastargetofnoveltreatmentstrategy
AT kimuranaoki musclefibernecroptosisinpathophysiologyofidiopathicinflammatorymyopathiesanditspotentialastargetofnoveltreatmentstrategy
AT umezawanatsuka musclefibernecroptosisinpathophysiologyofidiopathicinflammatorymyopathiesanditspotentialastargetofnoveltreatmentstrategy
AT hasegawahisanori musclefibernecroptosisinpathophysiologyofidiopathicinflammatorymyopathiesanditspotentialastargetofnoveltreatmentstrategy
AT yasudashinsuke musclefibernecroptosisinpathophysiologyofidiopathicinflammatorymyopathiesanditspotentialastargetofnoveltreatmentstrategy